Introduction {#s1}
============

Primary poorly differentiated neuroendocrine carcinoma/small cell carcinoma of the breast (SCCB) is a distinct subtype of breast cancer, accounting for \<1% of cases of primary breast cancer. SCCB belongs to the class of tumors known as extra-pulmonary small cell carcinomas, which have also been described in the urinary bladder, prostate, esophagus, stomach, colon, rectum, gallbladder, larynx, salivary glands, cervix, and skin. The first primary case was described by Wade et al. in 1983 ([@B1]). Although it typically presents in women, there have been a few cases of primary SCCB in males reported in the literature ([@B2]). SCCB has been diagnosed in patients aged 29--81 years ([@B3], [@B4]) who present with a palpable breast mass. The histologic characteristics of mammary SCC are similar to SCC arising in other organs. The diagnosis of primary mammary SCC can be made if a non-mammary metastasis to the breast is excluded, or an *in situ* component is identified histologically.

Below we describe a case of a 50-year old postmenopausal women with early stage primary SCCB of the right breast without lymph node involvement. Following treatment, she remained disease-free for 3 years, but developed a right lower lobe nodule and enlarged sub-carinal lymph node, which was treated like limited small cell lung cancer (SCLC). This case is unique in that the invasive SCCB was associated with an *in situ* component which was also purely of neuroendocrine differentiation.

Case Presentation {#s2}
=================

A 50-year-old G4P3 premenopausal South Asian woman with a history of gastroesophageal reflux disease and polycystic ovarian syndrome initially presented with a painful, palpable mass in the upper outer quadrant of the right breast noticed on self-breast exam. The patient was a lifelong non-smoker and did not report use of oral contraceptives or hormone replacement therapy. She had no personal or family history of breast or ovarian cancers and had a normal screening mammogram 1 year prior to presentation.

Clinical examination revealed an irregular, firm 2.4 cm mass in the upper outer quadrant of the right breast, approximately 9.5 cm from the nipple. There were no changes of the overlying skin or nipple or palpable axillary adenopathy. Her lungs were clear to auscultation; abdominal exam was without masses and no inguinal, cervical or contralateral axillary adenopathy were palpated. Diagnostic mammogram and ultrasound ([Figures 1A,B](#F1){ref-type="fig"}) indicated a 2.3 × 1.3 × 2.3 cm irregular mass in the upper outer quadrant of the right breast, highly suggestive of malignancy. Ultrasound guided core needle biopsy revealed poorly differentiated neuroendocrine carcinoma/small cell carcinoma ([Figures 2A,B](#F2){ref-type="fig"}), estrogen receptor (ER) negative, progesterone receptor (PR) positive (10% weak intensity), and human epidermal growth receptor 2 (HER2) negative. Immuno-histochemical staining was positive for thyroid transcription factor 1 (TTF-1), synaptophysin and chromogranin A, and rare cells positive for GATA3, consistent with primary SCCB ([Figures 2C,D](#F2){ref-type="fig"}). Importantly, and uniquely, an *in situ* component was identified (highlighted by the myoepithelial marker p40) which was also of purely neuroendocrine differentiation, which was conclusive evidence that this was a primary SCC of the breast. Due to the rarity of the case, these findings were confirmed at MD Anderson Cancer Center.

![**(A)** Diagnostic Mammogram: Right medio-lateral oblique view showing an irregular high density mass in the superior central aspect of the right breast. **(B)** Ultrasonography of right breast and axilla: Irregular hypoechoic macro-lobulated mass in the superior central aspect of the right breast.](fendo-11-00228-g0001){#F1}

![**(A)** Histopathological examination of the specimen stained on low (4x), **(B)** high power field (20x, 40x) showed neoplastic cells with high nuclear: cytoplasmic ratio, hyperchromatic nuclei, minimal cytoplasm, and indistinct nuclei, nuclear molding, high mitotic rate, consistent with the diagnosis of small cell carcinoma. Biopsy of breast cancer primary. Immuno-histochemical staining for TTF-1 synpatophysin, chromogranin, and p40 and smooth muscle myosin staining (SMMS) consistent with a diagnosis of primary SCCB, **(C)** small cell synaptophysin 20X. **(D)** small cell TTF-1 20X. **(E)** *In situ* component with neuroendocrine differentiation p40. **(F)** *in situ* component smooth muscle myosin stain. **(G)** Histopathological examination of the fine needle aspiration of the sub-carinal node revealed metastatic small cell carcinoma (Lymph node 40x).](fendo-11-00228-g0002){#F2}

Radiologic workup was conducted to exclude a non-mammary primary tumor origin and to complete staging for the breast cancer. Additionally, a positron emission tomography (PET) computerized tomography (CT) scans showed no evidence of lung, pancreatic, adrenal, or pelvic masses ([Figures 3A,B](#F3){ref-type="fig"}). Plasma neuropeptide levels revealed elevations in gastrin (207 pg/ml; normal 0--125 pg/ml), substance P (382 pg/ml; normal 0--240 pg/ml) and neurotensin (306 pg/ml; normal \<100 pg/ml). Plasma glucagon levels were also elevated (plasma neuropeptides or tumor markers are not required for the diagnosis). Germline genetic testing revealed a MUTYH E480 non-sense mutation which is associated with autosomal recessive MUTYH associated polyposis and would not be pathogenic when heterozygous with wild-type.

![**(A)** PET CT scan showing the primary lesion in the right upper outer quadrant of the right breast. **(B)** A hyper metabolic right axillary lymph node, which is compatible with the patient\'s known right breast primary malignancy and a presumed metastatic right axillary lymph node. **(C)** PET scan after recurrence showing new lung nodules with FDG uptake. **(D)** PET scan after recurrence showing sub-carinal lymph node with new intense focus of FDG uptake.](fendo-11-00228-g0003){#F3}

Based on the early clinical stage, the patient underwent a right lumpectomy with axillary lymph node dissection. Pathology revealed a poorly differentiated neuroendocrine carcinoma/ small cell carcinoma, ER/PR and HER2, were repeated on the resection specimen and were all negative with Ki-67 proliferation index of 70%. In addition, a high grade neuroendocrine *in situ* component was identified ([Figures 2E,F](#F2){ref-type="fig"}). Immuno-histochemical staining was positive for chromogranin A, CD56, synaptophysin and TTF-1 and, notably, the *in-situ* component was also positive for TTF-1. Tumor infiltrating lymphocytes (TILs) were low positive for PD-1 staining (1--24%) and tumor cells and TILs were negative for PD-L1 staining (antibody used for PD-L1 was clone 22C3 through Foundation One). The surgical margins were free of tumor and twelve lymph nodes were negative. The patient was diagnosed with primary SCCB (stage IIA).

Foundation One testing for mutations in thirty-five genes revealed the presence of a pathogenic variant in the MUTYH gene (c.1438G\>T, p.Glu480^\*^), loss of exons 19-27 in RB1, SMARCA4 P1975 mutation, and Tp53 R110_L111insL mutation as well as amplification in PIK3CA, FLT3, MYC, SOX2 and CDK8. She subsequently received adjuvant chemotherapy with four cycles of cisplatin 80 mg/m^2^ on day 1 and etoposide 100 mg/m^2^ on days 1, 2, and 3 of a 21-day cycle. She received right whole breast radiation therapy in the form of 5000cGy in 25 fractions followed by a 1000cGy boost in 5 fractions (6000cGy cumulative) to the surgical site.

Following treatment, the patient remained disease-free for 3 years, as evidenced by lack of clinical evidence of recurrence and negative imaging. Routine follow-up CT scans of the thorax showed a right lower lobe nodule and enlarged sub-carinal lymph node, which showed FDG avidity by PET scan ([Figures 3C,D](#F3){ref-type="fig"}). Bronchoscopy and trans-bronchial fine needle aspiration of the sub-carinal node revealed metastatic small cell carcinoma with Ki-67 staining in \>90% of cells ([Figure 2G](#F2){ref-type="fig"}). PD-L1 tumor proportion score was 0%. Repeat Foundation One testing performed on the slide from the sub-carinal lymph node revealed microsatellite stable status with a tumor mutation burden of 4 mutations/Mb, with amplifications noted in the CDK8, EPHB1, FLT3, MYC, PIK3CA, PIK3CB, RAD21 and SOX2 and loss of Rb and a MUTYH p E466 non-sense mutation.

She was treated with one cycle of cisplatin (80 mg/m^2^ on day 1) and etoposide 100mg/m^2^ on day 1-3) followed by one cycle concurrent with 45Gy external beam irradiation to the right lower lobe and mediastinum in 30 twice daily fractions. Follow-up CT scan of the chest revealed resolution of the right lower lobe nodule with residual scarring and significant decrease in size of the previously enlarged sub-carinal lymph node. She was then treated with two cycles of cisplatin-etoposide and two cycles of carboplatin-etoposide and concurrent atezolizumab, similar to the regimen used in the IMpower133 trial ([@B5]) for extensive stage small cell lung cancer but without maintenance atezolizumab, with radiologically and clinically stable disease and the MRI brain had no evidence of CNS metastases.

Discussion {#s3}
==========

Primary SCCB is a rare, aggressive form of breast carcinoma, with only 56 cases reported in the literature ([Table 1](#T1){ref-type="table"}). It typically presents as a palpable breast or axillary mass in women over the age of 60, with lymph node involvement in 50--67% of cases at the time of diagnosis ([@B33]). Primary SCCB has similar histologic, morphologic and immune-histochemical features to SCLC, including the expression of TTF-1 in up to 50% of cases. The diagnosis of SCCB requires the clinical exclusion of a metastasis from a non-mammary primary site, or identification of an *in situ* component.

###### 

Case reports of primary small cell neuroendocrine breast carcinoma.

  **References**                   **Age at diagnosis**   **Stage at diagnosis**   **Primary treatment**                             **Adjuvant treatment**                                                                                          **Outcome**                                                                  **Follow up (months)**
  -------------------------------- ---------------------- ------------------------ ------------------------------------------------- --------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------- ------------------------
  Wade et al. ([@B1])              52                     4 (mets to liver)        Modified radical mastectomy                       Doxorubicin, vincristine, cyclophosphomide                                                                      Death from metastatic disease                                                9
  Jundt et al. ([@B6])             52 (male)              4                        Chemo/XRT                                         None                                                                                                            Died from metastatic disease to the spine                                    14
  Papotti et al. ([@B7])           50                     3                        Mastectomy                                        Streptozotocin                                                                                                  Died from metastatic disease                                                 14
                                   68                     3                        Mastectomy                                        Tamoxifen                                                                                                       Died from cerebral hemorrhage                                                9
                                   41                     3                        Mastectomy                                        XRT                                                                                                             Died from metastatic disease                                                 15
                                   64                     1                        Lumpectomy                                        None                                                                                                            Alive without disease                                                        44
  Francois et al. ([@B8])          68                     2                        Modified radical mastectomy                       Chemo, XRT                                                                                                      Death from metastatic disease                                                21
  Chua et al. ([@B9])              45                     2                        Lumpectomy                                        NR                                                                                                              NR                                                                           NR
  Fukunaga and Ushigome ([@B10])   56                     3                        Mastectomy                                        None                                                                                                            Alive without disease                                                        48
  Sebenik et al. ([@B11])          67                     2                        Chemotherapy                                      XRT                                                                                                             Alive without disease                                                        33
  Samli et al. ([@B12])            60                     3                        Fluorouracil, epirubicine, and cyclophosphamide   Left modified radical mastectomy, axillary lymph node dissection, XRT, cisplatin/etoposide + FEC (x 4 cycles)   Alive with metastatic disease                                                9
  Shin et al. ([@B13])             64                     1                        Lumpectomy                                        Chemo                                                                                                           Alive without disease                                                        10
                                   57                     2                        Mastectomy                                        Chemo                                                                                                           Alive without disease                                                        10
                                   44                     2                        Lumpectomy                                        Chemo/XRT                                                                                                       Alive without disease                                                        27
                                   62                     3                        Neo-adjuvant chemo                                Mastectomy, adjuvant chemo, tamoxifen                                                                           Alive with metastatic disease                                                32
                                   70                     3                        Lumpectomy                                        Chemo/XRT                                                                                                       Alive without disease                                                        3
                                   46                     3                        Mastectomy                                        Chemo                                                                                                           Alive with metastatic disease                                                11
                                   51                     1                        Lumpectomy                                        XRT                                                                                                             Alive without disease                                                        25
                                   43                     1                        Lumpectomy                                        XRT                                                                                                             alive without disease                                                        30
                                   50                     3                        Lumpectomy                                        Chemo/tamoxifen                                                                                                 Alive without disease                                                        35
  Yamasaki et al. ([@B14])         41                     2                        Mastectomy                                        Cyclophosphamide, methotrexate, fluorouracil                                                                    Alive without disease                                                        16
  Hoang et al. ([@B15])            41                     NR                       Mastectomy                                        NR                                                                                                              NR                                                                           NR
                                   51                     NR                       Lumpectomy                                        NR                                                                                                              NR                                                                           NR
  Salmo and Connolly ([@B16])      46                     2                        Lumpectomy                                        Etoposide/cisplatin, XRT                                                                                        Alive without disease                                                        9
  Bergman et al. ([@B17])          61                     3                        mastectomy                                        NR                                                                                                              NR                                                                           NR
  Bigotti et al. ([@B18])          56                     3                        Chemotherapy                                      Modified radical mastectomy, chemo                                                                              Death                                                                        14
  Jochems and Tjalma ([@B19])      71                     2                        Mastectomy                                        Tamoxifen                                                                                                       Alive without disease                                                        12
  Mariscal et al. ([@B20])         53                     3                        Cisplatin + etoposide                             Lumpectomy                                                                                                      Alive without disease                                                        6
  Sridhar et al. ([@B21])          58                     3                        Lumpectomy                                        Adriamycin, cisplatin, XRT                                                                                      Alive without disease                                                        18
  Yamamoto et al. ([@B22])         53                     3                        Mastectomy                                        None                                                                                                            Alive without disease                                                        34
                                   75                     3                        Mastectomy                                        CMF, tamoxifen                                                                                                  Alive without disease                                                        43
  Adegbola et al. ([@B23])         46                     1                        Lumpectomy                                        XRT, cisplatin+etoposide                                                                                        Alive without disease                                                        48
                                   60                     1                        Lumpectomy                                        XRT, cisplatin+etoposide                                                                                        Died from disease recurrence                                                 26
                                   61                     3                        Lumpectomy                                        XRT, cisplatin+etoposide                                                                                        Alive with metastatic disease                                                6
  Cabibi et al. ([@B24])           40                     2                        Lumpectomy                                        NR                                                                                                              NR                                                                           NR
  Stein et al. ([@B25])            54                     3                        Cisplatin+etoposide                               Lumpectomy, XRT                                                                                                 Alive without disease                                                        24
  Kitakata et al. ([@B26])         44                     3                        Modified radical mastectomy                       Epirubicin/cyclophosphomide                                                                                     Alive without disease                                                        22
  Shaco-Levy et al. ([@B27])       28                     1                        Lumpectomy                                        Chemo, XRT                                                                                                      NR                                                                           NR
  Kinoshita et al. ([@B28])        31                     3                        Adriamycin+docetaxel                              Modified radical mastectomy                                                                                     Died from metastatic disease                                                 6
  Sadanaga et al. ([@B29])         33                     2                        Mastectomy                                        epirubicin+cyclophosphomide, XRT                                                                                Alive without disease                                                        60
  Hojo et al. ([@B30])             60                     2                        Modified radical mastectomy                       None                                                                                                            Developed recurrence with metastatic disease and died despite chemotherapy   26
  Quiros Rivero et al. ([@B31])    41                     2                        FAC+taxol+etoposide                               Lumpectomy, XRT                                                                                                 Alive without disease                                                        20
  Rineer et al. ([@B4])            81                     3                        Irinotecan+carboplatin                            XRT                                                                                                             Alive with disease                                                           26
  Yamaguchi et al. ([@B32])        51                     2                        Mastectomy                                        Paclitaxel                                                                                                      Alive with metastatic disease                                                12
  Latif et al. ([@B33])            53                     2                        Carboplatin+etoposide                             MRM, XRT                                                                                                        Alive without disease                                                        NR
  Nicoletti et al. ([@B34])        40                     2                        Mastectomy                                        Adriamycin+cytoxan, carboplatin+etoposide, tamoxifen, anastrozole                                               Alive without disease                                                        96
  Kawanishi et al. ([@B35])        67                     1                        Lumpectomy                                        Anastrozole                                                                                                     Alive without disease                                                        12
  Boyd and Hayes ([@B36])          50                     2                        Mastectomy                                        Docetaxel+cyclophosphamide                                                                                      Alive with metastatic disease                                                36
  Ge et al. ([@B37])               39                     2                        Modified radical mastectomy                       Docetaxel+carboplatin                                                                                           Alive without disease                                                        NR
  Ochoa et al. ([@B38])            25                     4                        Cisplatin+etoposide                               Radiation to the breast                                                                                         Death from metastatic disease                                                6
  Puscas et al. ([@B39])           50                     3                        Farmorubicin+ cyclophosphomide+ taxotere          Mastectomy, XRT                                                                                                 Alive with metastatic disease                                                NR
  Jiang et al. ([@B2])             79 (male)              2                        Modified radical mastectomy                       Irinotecan+carboplatin                                                                                          Died from metastatic disease                                                 27
  Dalle et al. ([@B40])            47                     2                        Mastectomy                                        Cisplatin+etoposide, fluorouracil+epirubicin+ cyclophosphamide, tamoxifen                                       Alive without disease                                                        10
  Raber et al. ([@B41])            38                     3                        Carboplatin+etoposide                             Modified radical mastectomy                                                                                     Alive without disease                                                        15
  Tremelling et al. ([@B42])       65                     3                        Carboplatin+etoposide                             XRT                                                                                                             Alive without disease                                                        3
                                   61                     3                        Lumpectomy                                        XRT, cisplatin+etoposide                                                                                        Alive with metastatic disease                                                6

*NR, not reported*.

Due to the rarity and limited reports of primary SCCB, a standard approach to treatment is largely undefined. Treatment regimens in the literature include combinations of surgery, chemotherapy, radiation therapy, and endocrine therapy depending on tumor size and lymph node status. Hormonal therapy is added if the tumor expresses the appropriate receptors ([@B13], [@B23], [@B43]). More recent reports have described treatment with breast conservation therapy combined with either neo-adjuvant or adjuvant chemotherapy depending on the clinical scenario. Most adjuvant chemotherapy regimens include a platinum agent and etoposide, given that biologic markers of SCCB are similar to that of SCLC (see [Appendix](#SM1){ref-type="supplementary-material"} for discussion on characteristics of SCCB vs. SCLC and genomic studies in SCCB) ([@B23], [@B37], [@B38], [@B44]--[@B46]). However, some have reported using anthracycline and taxane based combinations typically used for invasive breast cancer ([@B23], [@B33], [@B47], [@B48]).

Our patient had a very high Ki-67, and she was treated with platinum based chemotherapy. The present report details a case of primary SCCB, as established with neuroendocrine markers on immuno-histochemical staining in combination with a solitary breast mass, lack of regional lymph node involvement and lack of evidence of any other masses in other organs on radiologic imaging, and importantly an *in situ* component which was of pure neuroendocrine differentiation, which is a rare finding. The patient was treated with breast conservation surgery, followed by systemic chemotherapy using carboplatin and etoposide along with radiation therapy. Unfortunately, the patient had a recurrence after 3 years with genomic studies indicating shared mutations consistent with a single primary and was treated with chemo-radiation similar to limited stage SCLC and is now in clinical remission. Her tumor also expressed an amplification of PIK3CA, which may serve as a therapeutic target in the future.

This case report sheds light on a rarely described disease and provides a comprehensive approach to diagnosis and management. Further studies, including genomic analyses are needed to better define this malignancy and to develop a standard treatment.
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